Supplementary Methods
Verification of HTA results by mRNA-Seq data: High-throughput RNA sequencing data of human liver and muscle tissues was obtained from GSE12946
1 . Sequencing reads were mapped over the exonic regions, allowing up to two nucleotide mismatches by SeqMap 2 . An exon expression index was calculated as the number of reads per kilobase per million reads (RPKM) using only uniquely mapped reads 3 . A gene expression index was computed in a similar way using reads aggregated from all exons that belong to the gene.
To verify HTA analyses, one robust set of alternatively spliced exons and another robust set of non-spliced exons were determined from the mRNA-Seq data, using p-values from statistical tests for relative over-expression of exons (p), the number of mapped reads (n), and fold changes of exon expression normalized to gene expression (f). The over-expression of exons relative to gene expression was tested by Fisher's exact tests 4 . For a simple comparison between two conditions (C1 and C2), an exon is determined to be strictly over-expressed in C1 if p < 0.001, n ≥ 20 and f > 2, or strictly not over-expressed in C1 if p > 0.5, n in the C2 ≥ 20, and the exon has the larger normalized expression in C2 than in C1. For both conditions, four sets (strictly overexpressed in C1, strictly not over-expressed in C1, strictly over-expressed in C2, and strictly not over-expressed in C2) were determined, and exons that were not in any of four sets were classified to be not determinable. If an exon detected to be over-expressed in one condition by a microarray analysis is also determined to be strictly over-expressed in the same condition in mRNA-Seq data, it is counted as a true positive (TP). If it is determined to be strictly not overexpressed in the same condition, it is counted as a false positive (FP). The verification rate is defined as (# of TPs)/(# of TPs + # of FPs).
Several mRNA-Seq tools for alternative splicing analysis, such as Cufflinks 5 , Casper 6 , and DiffSplice 7 , are based on the estimation of isoform-level expression. An objective for RASA is to identify specific exons as alternative splicing candidates that can be verified using RT-PCR.
Since it is not easy to confidently extract exon-level alternative splicing events from the isoformlevel differential expression, we employed a conservative method to check the alternative splicing of each exon based on the number of mapped reads, expression fold changes, and statistical tests using Fisher's exact tests, which have been used in many previous works 1, 4, 8, 9 .
ASPIRE and ASI method: The proposed method was compared with the analysis of splicing by isoform reciprocity (ASPIRE) algorithm 10, 11 , and the accumulated splicing index (ASI) 12 . For the alternative splicing score of an exon, ASPIRE calculates an inclusion ratio using both inclusion and exclusion junctions of the exon. ASI calculates the sum of splicing indices of an exon and all of its junctions as the score. Both ASPIRE and ASI detect top several exons ranked by their scores as confident candidates of alternative splicing. While ASI was tested over all exons, ASPIRE was tested over a subset of exons whose exclusion junctions are available because ASPIRE requires exclusion junctions in its calculation.
RT-PCR validation: Primer pairs were designed using Primer3 package, and manually reviewed 
